Webinar: Leveraging the Unique Combination of Bioanalysis and Spatial Bioanalysis to Accelerate Drug Development
The risk of failure in research leading to the development of new drugs is significant, with an overall likelihood of approval (LOA) from Phase I at 8% for all development candidates. Pharmaceutical companies need support early in this process to demonstrate the efficacy and safety of their drugs, to obtain faster approval by the regulatory agencies.
Pyxant Labs and ImaBiotech (the newly formed global bioanalytical services provider); encompass high-performance bioanalytical GLP services, proprietary drug and biomarker imaging, and spatial biology services; to deliver a unique offering to pharmaceutical companies. These services are translatable from early-stage discovery through Phase IV to study the toxicity, penetration, pharmacokinetics, and pharmacodynamics of compounds and our core of excellence in bioanalytical service reduces the rate of failure and accelerates the development of safer therapies.
Throughout this presentation, we will demonstrate the power of Mass Spectrometry and its versatility across various types of drug molecules. In addition, the combination of Imaging Mass Spectrometry and Spatial omics platforms to measure drug exposure and biomarker response will be presented. This webinar will highlight the ability of these platforms to decipher the complexity of drug activities at single cell level in heterogeneous tissues to measure efficacy.
TUESDAY, SEPTEMBER 14th 2021
- EUROPE TIME: 5PM CET
- USA TIME: 11AM EST
Conference animated by
Shane Karnik: Senior Laboratory Director @Pyxant Labs
David Bonnel: Global Executive Director @imabiotech